Open AccessEpirubicin in der Kombinations-Chemotherapie des metastasierten Mammakarzinoms (VEC) und des fortgeschrittenen Ovarialkarzinoms (PEC)
Author(s) -
D Christmann
Publication year - 1986
Publication title -
oncology research and treatment
Language(s) - German
Resource type - Journals
SCImago Journal Rank - 0.553
H-Index - 48
eISSN - 2296-5262
pISSN - 2296-5270
DOI - 10.1159/000216055
Subject(s) - epirubicin , medicine , cyclophosphamide , breast cancer , doxorubicin , oncology , vincristine , chemotherapy , cisplatin , metastatic breast cancer , cancer
Epirubicin was applied in combination with vincristine and cyclophosphamide (VEC) against metastatic cancer of the breast in 14 patients, against advanced cancer of the ovaries. Epirubicin was applied in combination with cisplatin and cyclophosphamide (PEC) in 12 patients. Treatment of metastatic cancer of the breast achieved retrogression in 64%, the tumor was brought to a standstill in 12%. Treatment of cancer of the ovaries achieved complete retrogression in 75%, the tumor was brought to a standstill in 8.3%. There was no incidence of considerable myelo- or cardiotoxic side effects resulting in a necessary interruption of treatment. The achieved results of this treatment correspond to those with doxorubicin combinations, the toxicity, however, is less.